HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
De León-Crutchlow Publications
Below are selected publications from the De León-Crutchlow Lab.
States LJ, Becker SA, De León DD. Congenital hyperinsulinism: localization of a focal lesion with 18F-FDOPA positron emission tomography. Pediatr Radiol. 2022 Apr; 52(4):693-701. Epub 2021 Oct 19. PMID: 34668049.
Stefanovski D, Vajravelu ME, Givler S, De León DD. Effects on glucose and insulin in children with congenital hyperinsulinism during fasting and during a meal and a protein challenge. Diabetes Care. 2022 Apr; dc212009. Epub ahead of print. PMID: 35416981.
Rayannavar A, Mitteer LM, Balliro CA, El-Khatib FH, Lord KL, Hawkes CP, Ballester LS, Damiano ER, Russell SJ, De León DD. The Bihormonal Bionic Pancreas improves glycemic control in individuals with hyperinsulinism and postpancreatectomy diabetes: A pilot study. Diabetes Care. 2021 Nov; 44(11):2582-2585. Epub 2021 Sep 13. PMID: 34518377
Vajravelu ME, Lee JJ, Mitteer L, Zemel BS, Bittinger K, De León DD. Gut microbiome profile after pancreatectomy in infants with congenital hyperinsulinism. Pancreas. 2021 Jan; 50(1):89-92. PMID: 33370028
Soundarapandian MM, Juliana CA, Chai J, Haslett PA, Fitzgerald K, De León DD. Activation of Protein Kinase A (PKA) signaling mitigates congenital hyperinsulinism associated hypoglycemia in the Sur1-/- mouse model. PLoS One. 2020 Jul; 15(7):e0236892. PMID: 32735622
Rosenfeld E, Ganguly A, De Leon DD. Congenital hyperinsulinism disorders: Genetic and clinical characteristics. Am J Med Genet C Semin Med Genet. 2019 Dec; 181(4):682-692. PMID: 31414570
Boodhansingh KE, Kandasamy B, Mitteer L, Givler S, De Leon DD, Shyng SL, Ganguly A, Stanley CA. Novel dominant KATP channel mutations in infants with congenital hyperinsulinism: Validation by in vitro expression studies and in vivo carrier phenotyping. Am J Med Genet A. 2019 Nov; 179(11):2214-2227. PMID: 31464105
Rayannavar A, Elci OU, Mitteer L, De León DD. Continuous Glucose Monitoring Systems: Are They Useful for Evaluating Glycemic Control in Children with Hyperinsulinism?. Horm Res Paediatr. 2019 Jan; 92(5):319-327. PMID: 32208390
Vajravelu ME, Congdon M, Mitteer L, Koh J, Givler S, Shults J, De León DD. Continuous Intragastric Dextrose: A Therapeutic Option for Refractory Hypoglycemia in Congenital Hyperinsulinism. Horm Res Paediatr. 2019 Jan; 91(1):62-68. PMID: 30086540
Adzick NS, De Leon DD, States LJ, Lord K, Bhatti TR, Becker SA, Stanley CA. Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children. J Pediatr Surg. 2019 Jan; 54(1):27-32. PMID: 30343978
Herrera A, Vajravelu ME, Givler S, Mitteer L, Avitabile CM, Lord K, De León DD. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. J Clin Endocrinol Metab. 2018 Dec; 103(12):4365-4372. PMID: 30247666
Tung JY, Boodhansingh K, Stanley CA, De León DD. Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations. Pediatr Diabetes. 2018 Aug; 19(5):910-916. PMID: 29493090
Patel P, Charles L, Corbin J, Goldfine ID, Johnson K, Rubin P, De León DD. A unique allosteric insulin receptor monoclonal antibody that prevents hypoglycemia in the SUR-1-/- mouse model of KATP hyperinsulinism. MAbs. 2018 Jul; 10(5):796-802. doi: 10.1080/19420862.2018.1457599. PMID: 29589989
Vajravelu ME, Chai J, Krock B, Baker S, Langdon D, Alter C, De León DD. Congenital Hyperinsulinism and Hypopituitarism Attributable to a Mutation in FOXA2. J Clin Endocrinol Metab. 2018 Mar; 103(3):1042-1047. PMID: 29329447
Li C, Ackermann AM, Boodhansingh KE, Bhatti TR, Liu C, Schug J, Doliba N, Han B, Cosgrove KE, Banerjee I, Matschinsky FM, Nissim I, Kaestner KH, Naji A, Adzick NS, Dunne MJ, Stanley CA, De León DD. Functional and Metabolomic Consequences of KATP Channel Inactivation in Human Islets. Diabetes. 2017 Jul; 66(7):1901-1913. PMID: 28442472
Ferrara CT, Boodhansingh KE, Paradies E, Fiermonte G, Steinkrauss LJ, Topor LS, Quintos JB, Ganguly A, De Leon DD, Palmieri F, Stanley CA. Novel Hypoglycemia Phenotype in Congenital Hyperinsulinism Due to Dominant Mutations of Uncoupling Protein 2. J Clin Endocrinol Metab. 2017 Mar; 102(3):942-949. Erratum in: J Clin Endocrinol Metab. 2018 May 1;103(5):2076. PMID: 27967291
Kalish JM, Boodhansingh KE, Bhatti TR, Ganguly A, Conlin LK, Becker SA, Givler S, Mighion L, Palladino AA, Adzick NS, De León DD, Stanley CA, Deardorff MA. Congenital hyperinsulinism in children with paternal 11p uniparental isodisomy and Beckwith-Wiedemann syndrome. J Med Genet. 2016 Jan; 53(1):53-61. PMID: 26545876
Lord K, Dzata E, Snider KE, Gallagher PR, De León DD. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1786-9. PMID: 24057290
Calabria AC, Li C, Gallagher PR, Stanley CA, De León DD. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. 2012 Oct; 61(10):2585-91. PMID: 22855730
Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012 Oct; 97(10):E2026-30. PMID: 22802087